Raymond, A;
Vadgama, S;
Utley, M;
Morris, S;
(2019)
Evaluation of the NHS England Innovation Test Bed at Care City.
(Publications: reports
).
Care City: Barking, London.
![[thumbnail of Care City Test Bed Final Evaluation Report_Main Report)fromCareCityWebsite.pdf]](https://discovery-pp.ucl.ac.uk/style/images/fileicons/text.png) |
Text
Care City Test Bed Final Evaluation Report_Main Report)fromCareCityWebsite.pdf - Published Version Access restricted to UCL open access staff Download (779kB) |
Abstract
Care City is an innovation centre focused on healthy ageing and social regeneration in outer North East London. The Care City Test Bed had the stated aim of promoting the adoption of technology and other innovations to have a marked beneficial impact on the sustainability of health and social care services among those aged 65 and over in this region through work in three clusters: long-term conditions, dementia and carer resilience. In its long term conditions cluster, Care City supported the adoption of technology to improve access to preventative services relevant to falls and stroke. It also sought to facilitate the adoption of innovation to identify and support people that could benefit from early intervention to increase self-care, with a view that this would improve health outcomes and reduce demand on health and social care services in the medium to long term. In its dementia cluster, Care City set out to facilitate access to innovations intended to support more person-centred care, and peer-to-peer support intended to reduce isolation. Reflecting the fact that deprived communities benefit less from research and the participation in research, Care City sought to boost local participation of its population in dementia research. Recognising the increasingly valuable role played by informal carers in supporting the work of the health and social care system, Care City was keen to explore how innovation could improve the support available to them. Care City’s ambition was to conduct real world testing of innovations, with funding of innovations on business-as-usual terms and with innovations tested in routine clinical settings, and with innovations or their use adapted in response to the findings of iterative testing.
Archive Staff Only
 |
View Item |
